Miravant Medical Technologies  

(Public, OTCMKTS:MRVT)   Watch this stock  
Find more results for PINK:MRVT
Feb 6 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol / Avg. 0.00/0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.41
Shares 37.86M
Beta     -
Inst. own 0%

Key stats and ratios

Q3 (Sep '05) 2004
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -191.26% -320.68%
Return on average equity - -
Employees 47 -
CDP Score - -


336 Bollay Drive
United States - Map
+1-805-6859880 (Phone)
+1-805-6857981 (Fax)


Miravant Medical Technologies is a pharmaceutical research and development company engaged in photodynamic therapy (PDT), a treatment modality based on drugs that respond to light. The drug and light procedures involve three components, the photoselective drugs, light producing devices and light delivery devices. The Company's products have been developed in-house and with outside collaborators and have been used in various clinical and preclinical investigations. Its most advanced drug, PHOTREX, generic name rostaporfin, has completed two Phase III clinical trials for the treatment of wet age-related macular degeneration (AMD). Miravant has branded its version of PDT technology with the trademark PhotoPoint.

Officers and directors

John M. Philpott Chief Financial Officer, Treasurer, Assistant Secretary
Age: 50
David E. Mai President, Director
Age: 65
Robert J. Sutcliffe Non-Executive Chairman of the Board
Age: 60
Nuno Brandolini Director
Age: 60
Michael Khoury Director
Age: 59
Kevin R. McCarthy Director